EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice

Angelo Ruggiero iD, Raffaele Mozzillo, Mario Cordedda, Elisa Camela iD, Renato Zanchini, Paola Colasanti, Orlando Zagaria

Clinical and Experimental Dermatology · 17.08.2026 · 51 (9) · 1654-1660

DOI: 10.1093/ced/llag187 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 25.04.2026. Verfasst von Angelo Ruggiero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare, Naples, Italy. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor, has demonstrated efficacy and safety in phase III clinical trials for moderate-to-severe plaque psoriasis. However, real-world evidence remains limited.

Objectives

To evaluate the effectiveness and safety of deucravacitinib in adult patients with moderate-to-severe plaque psoriasis treated in routine clinical practice.

Methods

We conducted a retrospective, single-centre, real-world observational study. Consecutive adult patients with ­moderate-to-severe plaque psoriasis who initiated deucravacitinib between December 2024 and December 2025 were retrospectively identified. At each follow-up Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), body ­surface area (BSA), numeric rating scale (NRS) pruritus. In addition, ≥ 75% improvement in PASI (PASI 75), ≥ 90% improvement in PASI (PASI 90) and 100% improvement in PASI (PASI 100) response rates were also evaluated. Safety was assessed through adverse event reporting and routine laboratory monitoring.

Results

In total, 46 patients completed the 24-week follow-up and were included in the study. Mean PASI decreased from 12.5 (SD 3.1) at baseline to 3.2 (SD 2.1) at week 24 (P < 0.001) and mean BSA decreased from 18.0% (SD 6.5%) to 5.0% (SD 3.6) (P < 0.001). NRS pruritus and DLQI also improved significantly over time (both P < 0.001). Of the 46 patients, PASI 75 was achieved by 70% (n = 32) at week 24, and PASI 90 and PASI 100 were achieved by 54% (n = 25) and 33% (n = 15), respectively. No serious adverse events or clinically relevant laboratory abnormalities were observed. Acne was the most frequent adverse event, occurring in 4 of 46 patients (9%), and was mild in all patients.

Conclusions

In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favourable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisHumansFemaleMaleRetrospective StudiesSeverity of Illness IndexMiddle AgedAdultTreatment OutcomeQuality of LifePruritusAged

Autor:innen und Institutionen

  • Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare, Naples, Italy.

ORCID-Profile: Angelo Ruggiero, Elisa Camela

Zitieren

APA

Ruggiero, A., Mozzillo, R., Cordedda, M., Camela, E., Zanchini, R., Colasanti, P., & Zagaria, O. (2026). Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice. Clinical and Experimental Dermatology, 51(9), 1654-1660. https://doi.org/10.1093/ced/llag187

Vancouver

Ruggiero A, Mozzillo R, Cordedda M, Camela E, Zanchini R, Colasanti P, et al. Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice. Clinical and Experimental Dermatology. 2026;51(9):1654-1660. doi:10.1093/ced/llag187

BibTeX
@article{Ruggiero2026,
  author = {Ruggiero, Angelo and Mozzillo, Raffaele and Cordedda, Mario and Camela, Elisa and Zanchini, Renato and Colasanti, Paola and Zagaria, Orlando},
  title = {Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  volume = {51},
  number = {9},
  pages = {1654--1660},
  doi = {10.1093/ced/llag187}
}
Kostenlos starten →